Patients must not be receiving any other investigational anti-cancer agents while on study
Patients must not be planning treatment with other systemic anti-cancer agents (e.g., chemotherapy, hormonal therapy, immunotherapy) or other treatments not part of protocol-specified anti-cancer therapy including concurrent investigational agents of any type
Previous anti-cancer chemotherapy, immunotherapy or investigational agents =<  days prior to registration
Receiving any other investigational agents or any other anti-cancer therapy
Has received prior systemic anti-cancer therapy including investigational agents for the current malignancy prior to randomization/allocation.
Has received prior systemic anti-cancer therapy including investigational agents within  weeks prior to study start
Patients may not be receiving any systemic anti-cancer agents or other investigational agents during radiation therapy
Patients who are receiving any other anti-cancer or investigational drug therapy are ineligible
Subjects who require warfarin, anti-cancer therapeutics or investigational agents
Has received prior systemic anti-cancer therapy including investigational agents within  weeks prior to study enrollment
Receiving any other investigational agents or any other anti-cancer therapy
Patients may not be receiving the concomitant administration of any systemic therapy, biologic therapy, or other agents with anti-tumor activity against prostate cancer while the patients are on study.
Participants who are receiving any other investigational agents, or any other anti-cancer therapy during study treatment
Prior anti-tumor therapy within  weeks of cycle  day  (anti-tumor therapy defined as, but is not limited to, anti-cancer agents (cytotoxic chemotherapy, immunotherapy, and biologic therapy), radiotherapy, and investigational agents), the wash-out period
Participants who are receiving any other investigational agents or have received investigational therapy or any anti-cancer monoclonal antibody (mAB) within  weeks prior to the st dose of pembrolizumab
Receiving other anti-cancer or investigational therapy during study treatment, apart from those agents specified in the study protocol
Patients receiving concurrent anti-cancer treatment (chemotherapy, investigational agents, immunotherapy, endocrine therapy, or Optune)
Patients may not be receiving any other investigational and/or anti-cancer agents
Patients must NOT receive other anti-cancer agents while on study
For purposes of this protocol, anti-tumor treatment may be defined as, but is not limited to, anti-cancer agents (cytotoxic chemotherapy, immunotherapy, biologic therapy), radiotherapy, and investigational agents; an investigational agent is any drug or therapy not currently approved for use in humans\r\n* Anti-cancer agents: anti-cancer agents are not permitted within  days prior to start of POPI; there are no limitations on the type or number of prior regimens; hormonal therapy and trastuzumab are permitted during POPI\r\n* Radiation: prior treatment with breast irradiation is not allowed \r\n* Surgery: incident breast biopsies only permitted prior to POPI to confirm residual disease after NAC
Patients receiving any other investigational agents or anti-cancer agents within  days other than mibefradil dihydrochloride, hypofractionated RT, or corticosteroids as described in this clinical protocol during treatment
Concomitant therapy with any anti-cancer agents, other investigational anti-cancer therapies, or immunosuppressive agents including but not limited to methotrexate, chloroquine, azathioprine, etc. within six months of study participation
Any anti-cancer therapy or investigational agents =<  weeks prior to registration
Concomitant therapy with any anti-cancer agents, other investigational anti-cancer therapies, or immunosuppressive agents; chronic use of systemic corticosteroids
Participants who are receiving any other study or off protocol anti-cancer agents
Previous anti-cancer chemotherapy, immunotherapy or investigational agents <  weeks prior to the first day of study defined treatment
Patients must not be planning to receive other anti-cancer agents including investigational agents while on protocol treatment
More than  prior systemic anti-cancer therapies (e.g. cytotoxic agents, biologic agents) regimens for metastatic disease
No concomitant approved anti-cancer therapies or any investigational agents
Patients with any number of prior therapies with anti-angiogenic agents or immunotherapy with the exception of any previous anti-CTLA- directed agents are allowed; a  week washout period is required for all agents, except for bevacizumab where a  week washout is required
Patients who are receiving any other anti-cancer or investigational drug therapy are excluded
Concurrent anti-cancer therapy, including chemotherapy agents, targeted agents, or biological agents not otherwise specified in this protocol
Patients receiving any other investigational agents or any additional anti-cancer agents
Patients may not be receiving any other investigational agents; patients cannot be receiving concomitant chemotherapy, radiotherapy, experimental therapy or any other therapy for the purposes of anti-cancer treatment
Treatment with systemic biologic therapy for prostate cancer (other than approved bone targeted agents and GnRH-analogue therapy) or other agents with anti-tumor activity within  weeks of enrollment (day  visit)
Other concomitant anti-cancer therapy agents excepts steroids
Anti-tumor therapy (i.e. chemotherapeutics or investigational agents or immunotherapy) within  weeks prior to enrollment
Other concomitant anti-cancer therapy agents except steroids
Concurrent chemotherapy, or targeted anti-cancer agents, other than hydroxyurea
Concurrent use of other anti-cancer therapy including chemotherapy agents, targeted agents, or biological agents not otherwise specified in this protocol
Patients may not be receiving any other investigational agents or any concomitant antineoplastic therapy, with the exception of androgen ablating agents (for patients with prior prostate cancer)
Patients receiving any other investigational anti-cancer agents
Receiving any other investigational agents or any other anti-cancer therapy
No concurrent anti-cancer treatment (including topical agents such as imiquimod) or investigational agents
All cancer patients receiving chemotherapy agents
Has received prior systemic anti-cancer therapy including investigational agents for the current malignancy.
Received treatment with chemotherapy, wide-field radiation, or anti-cancer biologic therapy including investigational agents within  days of study entry.
Current receipt of any other investigational agents or any additional anti-cancer agents for this or any other disease
Concurrent use of other anti-cancer therapy, including chemotherapy agents, targeted agents, biological agents, immunotherapy, or investigational agents not otherwise specified in this protocol
Receipt of any other investigational agents or any additional anti-cancer agents
Anti-cancer agents: must not be receiving other anti-cancer agents at time of enrollment and must not be planning to take other anti-cancer agents during DLT period